X
- No products in the list
The NGS Solid Tumor Panel truNGS® Solid Tumor Kit is a comprehensive next-generation sequencing assay for profiling solid tumors. It detects single nucleotide variants (SNVs), insertions/deletions (Indels), copy number variations (CNVs), and RNA fusions across 35 clinically actionable genes and six pharmacogenomics hotspots, including DPYD, UGT1A1, CYP2D6, MTHFR, TPMT, and CYP2C9.
Designed in line with NCCN and ESMO guidelines, the panel covers major solid tumor types such as lung, colorectal, liver, brain, melanoma, and head & neck cancers. Its hybrid capture design ensures full exon coverage, enabling the detection of both known and novel alterations.
Compatible with Illumina and MGI platforms, the panel requires minimal DNA and RNA input and offers reproducible results with >98% coverage uniformity. Integrated bioinformatics transforms raw sequencing data into clinical-grade reports in under 1.5 hours.
With a limit of detection (LoD) as low as 3.5% for SNVs, the NGS Solid Tumor Panel supports oncology labs in diagnostics, biomarker discovery, and personalized treatment planning.
The truNGS® Solid Tumor Panel Kit is a carefully curated assay covering 35 marker genes relevant to oncology, including EGFR, KRAS, NRAS, BRAF, TP53, ALK, ROS1, and RET. In addition, the panel includes hotspots for six pharmacogenomics genes—DPYD, UGT1A1, CYP2D6, MTHFR, TPMT, and CYP2C9—supporting drug metabolism and treatment optimization.
The panel is designed for use with formalin-fixed paraffin-embedded (FFPE) and fresh frozen tissues, requiring 100–200 ng DNA and 400–500 ng RNA. It spans 117 kb for DNA targets and 74 kb for RNA, offering broad coverage. The complete workflow includes library preparation, hybrid capture enrichment, sequencing, and integrated bioinformatics analysis.
Genetic alterations in solid tumors are key drivers of cancer initiation, progression, and therapeutic response. The NGS Solid Tumor Panel addresses clinically relevant variants associated with lung, colorectal, breast, liver, brain, melanoma, and head & neck cancers.
For example:
EGFR, ALK, ROS1, and RET variants guide targeted therapies in non-small cell lung cancer.
BRAF and NRAS mutations are actionable in melanoma and colorectal cancer.
IDH1 and IDH2 mutations provide insights into brain tumor biology.
By including pharmacogenomics genes, the panel also supports personalized therapy selection, identifying variants that affect the safety and efficacy of chemotherapeutic drugs.
The truNGS® Solid Tumor Panel is developed in alignment with NCCN and ESMO guidelines, ensuring clinical relevance and translational utility. The assay has been validated for high sensitivity (LoD as low as 3.5%), reproducibility (99.99%), and coverage uniformity (>98%).
This CE-marked panel provides oncology laboratories with confidence in variant detection. It is compatible with both Illumina and MGI sequencing platforms, requiring approximately 2.5 million reads per sample to achieve a mean coverage of 1000x. With a 1.5-day library preparation and automated reporting, laboratories can shorten turnaround time while maintaining accuracy.
The workflow combines DNA and RNA library preparation, hybrid capture target enrichment, and high-throughput sequencing. Key steps include:
DNA and RNA extraction from FFPE or fresh frozen tissue.
Library preparation with fragmentation, adapter ligation, and PCR amplification.
Target enrichment by hybrid capture, ensuring complete exon coverage and novel variant discovery.
Sequencing on Illumina or MGI platforms with 150 × 2 cycles chemistry.
Bioinformatics pipeline – alignment, variant calling, and clinical reporting in ~1.5 hours.
This streamlined process integrates seamlessly into oncology laboratory workflows, from raw sample to actionable clinical report.
The NGS Solid Tumor Panel supports a wide range of clinical and research applications:
Comprehensive tumor profiling – Detect actionable mutations in lung, colorectal, breast, liver, brain, melanoma, and head & neck cancers.
Therapeutic decision-making – Inform targeted treatment strategies with Level 1–3A clinical evidence (AACR).
Pharmacogenomics insights – Guide safe drug administration via hotspot detection in DPYD, UGT1A1, CYP2D6, MTHFR, TPMT, and CYP2C9.
Translational research – Enable discovery of novel biomarkers and support clinical trial enrollment.
By providing reliable, reproducible, and clinically actionable results, the truNGS® Solid Tumor Kit strengthens the role of precision oncology in patient care.
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.